Acquisition by Whiting Samuel of 100000 shares of Tempest Therapeutics at 4.66 subject to Rule 16b-3

TPST Stock  USD 0.76  0.03  3.80%   
Slightly above 50% of Tempest Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Tempest Therapeutics Officer: Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 100000 employee stock option (right to buy) at 4.66 of Tempest Therapeutics by Whiting Samuel on 2nd of May 2024. This event was filed by Tempest Therapeutics with SEC on 2024-01-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Tempest Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Tempest Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Tempest Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tempest Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tempest Therapeutics Fundamental Analysis

We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Tempest Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Tempest Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.

Peers

Tempest Therapeutics Related Equities

AKTXAkari Therapeutics   2.06   
0%
33.0%
ZNTLZentalis Pharmaceuticals   0.97   
0%
15.0%
IKNAIkena Oncology   0.62   
0%
10.0%
RVMDRevolution Medicines   0.16   
0%
2.0%
FBRXForte Biosciences   0.10   
0%
1.0%
INDPIndaptus Therapeutics   0.11   
1.0%
0%
ARMPArmata Pharmaceuticals   0.50   
8.0%
0%
PCSAProcessa Pharmaceuticals   1.49   
24.0%
0%
RNXTRenovoRx   2.34   
38.0%
0%
SANASana Biotechnology   2.55   
41.0%
0%
GLUEMonte Rosa   2.74   
44.0%
0%
LYELLyell Immunopharma   2.99   
48.0%
0%
RZLTRezolute   3.56   
58.0%
0%
OLMAOlema Pharmaceuticals   4.56   
74.0%
0%
CGEMCullinan Oncology   5.85   
95.0%
0%
ANEBAnebulo Pharmaceuticals   6.11   
100.0%
0%

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.